FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Authors

  • A.M. RUDZITE Riga Stradins University, Riga, Latvia
  • D. AUZINA Riga Stradins University, Riga, Latvia
  • S. LEJNIECE Riga Stradins University, Riga, Latvia

DOI:

https://doi.org/10.15407/exp-oncology.2024.03.260

Keywords:

COVID-19 mortality, COVID-19 risk factors, hematological malignancies

Abstract

Background. Patients with hematological malignancies (HM) are considered to have a high risk of developing severe and life-threatening infections including COVID-19 because of immune deficiency and immunosuppressive treatments. Although the COVID pandemic spread worldwide, morbidity and mortality data varied from country to country. A more accurate identification of risk factors would allow the improvement of the clinical management of HM patients. Aim. This study aimed to determine real-life data — the mortality rate, clinical outcomes, and risk factors affecting mortality in patients with HM and COVID-19 at the Riga East University Hospital (REUH) in Latvia. Materials and Methods. In this retrospective non-interventional cohort study, we included adult patients treated in REUH with ongoing HM and laboratory- confirmed COVID-19 observed between December 1st, 2020, and March 31st, 2023. All data were analyzed using descriptive statistics, binary logistic regression, univariable Cox regression model, and other methods. Results. We registered 156 patients with 11 different HMs. Multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia were the most common HM. COVID-19 mortality rate was 19.9% (31/156). Factors increasing the risk of death included the severity of COVID-19 (p < 0.001), the accession of bacterial infection (p < 0.001), longer hospital stay (p = 0.037), absolute neutrophil count (ANC) ≤ 0.5 × 109/mm3 (p = 0.014), fever (p = 0.039), and acute myeloid leukemia (p = 0.002). We also confirmed that the mortality in the third pandemic wave was significantly lower than in the second wave (p = 0.002). Although vaccination seemed to be a risk-mitigating factor (58.8% [10/17] of those who died from COVID-19 were not vaccinated), no statistically important correlation was found (p = 0.690). Conclusion. This survey confirmed that the COVID-19 mortality rate was higher in patients with HM (19.9% [31/156]) than in the population. ANC, severity of COVID-19, accession of bacterial infection, hospital stay, fever, and acute myeloid leukemia were the factors that increased mortality in HM patients.

References

Cucinotta D, Vanelli M. WHO declares COVID­19 a pandemic. Acta Biomed. 2020;91(1):157­160. https://doi. org/10.23750/abm.v91i1.9397

COVID­19 excess mortality collaborators. Estimating excess mortality due to the COVID­19 pandemic: a syste­ matic analysis of COVID­19­related mortality, 2020­21. Lancet. 2022;399(10334):1513­1536. https://doi.org/10.1016/ S0140­6736(21)02796­3

Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID­19: a systematic review and meta­analysis of 3377 patients. Blood. 2020;136(25):2881­2892. https://doi.org/10.1182/blood.2020008824

Henley SJ, Dowling NF, Ahmad FB, et al. COVID­19 and other underlying causes of cancer deaths — United States, January 2018–July 2022. MMWR. 2022;71:1583­1588. http://dx.doi.org/10.15585/mmwr.mm7150a3

Hosseini­Moghaddam SM, Shepherd FA, Swayze S, et al. SARS­CoV­2 infection, hospitalization, and mor­ tality in adults with and without cancer. JAMA Netw Open. 2023;6(8):e2331617. https://doi.org/10.1001/jamanet­ workopen.2023.31617

Marchesi F, Salmanton­García J, Emarah Z, et al. COVID­19 in adult acute myeloid leukemia patients: a long­term fol­ low­up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica. 2023;108(1):22­ 33. https://doi.org/10.3324/haematol.2022.280847

Pagano L, Salmanton­García J, Marchesi F, et al. COVID­19 infection in adult patients with hematological malignan­ cies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. https://doi. org/10.1186/s13045­021­01177­0

ISSN 1812-9269. Experimental Oncology 46 (3). 2024

Latvijas Republikas valsts kontrole. 2022. Lēmumu pieņemšana un krīzes pārvaldība Covid­19 pandēmijas laikā. https://lrvk.gov.lv/lv/getrevisionfile/29552­V1Ejaf2ueRQ­bdU_­dZw4V_iLd5x_8Wa.pdf. Accessed March 28, 2024.

McIntosh K, Rajesh MD, Gandhi T et al. COVID­19: Clinical features. UpToDate. 2024. https://www­uptodate­com. db.rsu.lv/contents/covid­19­clinical­features?search=covid%2019%20severity&source=search_result&selectedTitle

=1%7E150&usage_type=default&display_rank=1 [Accessed March 25, 2024].

Johns Hopkins University & Medicine. Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/data/ mortality. [Accessed March 25, 2024].

Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS­CoV­2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137(26):3674­3676. https://doi. org/10.1182/blood.2021011904

Fan Y, Li X, Zhang L, et al. SARS­CoV­2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141. https://doi.org/10.1038/s41392­022­00997­x

Blair HA. Remdesivir: a review in COVID­19. Drugs. 2023;83(13):1215­1237. https://doi.org/10.1007/s40265­023­01926­0

Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID­19. Front Immunol. 2022;13:855496 https://doi.org/10.3389/fimmu.2022.855496.

Downloads

Published

19.12.2024

How to Cite

RUDZITE, A., AUZINA, D., & LEJNIECE, S. (2024). FACTORS AFFECTING COVID-19 OUTCOMES IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. Experimental Oncology, 46(3), 260–267. https://doi.org/10.15407/exp-oncology.2024.03.260

Issue

Section

Original contributions